Marcellin, P. Et Al. 2003. A phase III, partially double-blinded study evaluating the efficacy and safety of peginterferon alfa-2a (40KD) (PEGASYS (R)) alone or in combination with lamivudine vs lamivudine in 546 patients with HBeAg-negative/anti-HBe-positive chronic hepatitis B.. 54th Annual Meeting of the American-Association-for-the-Study-of-Liver-Disease , (BOSTON, MASSACHUSETTS).

Marcellin, P., Lau, G., Bonino, F., Farci, P., Hadziyannis, S., Jin, R., ... Lu, Z.(2003). A phase III, partially double-blinded study evaluating the efficacy and safety of peginterferon alfa-2a (40KD) (PEGASYS (R)) alone or in combination with lamivudine vs lamivudine in 546 patients with HBeAg-negative/anti-HBe-positive chronic hepatitis B. . 54th Annual Meeting of the American-Association-for-the-Study-of-Liver-Disease, BOSTON, MASSACHUSETTS

Marcellin, P Et Al. "A phase III, partially double-blinded study evaluating the efficacy and safety of peginterferon alfa-2a (40KD) (PEGASYS (R)) alone or in combination with lamivudine vs lamivudine in 546 patients with HBeAg-negative/anti-HBe-positive chronic hepatitis B.," 54th Annual Meeting of the American-Association-for-the-Study-of-Liver-Disease, BOSTON, MASSACHUSETTS, 2003

Marcellin, P Et Al. "A phase III, partially double-blinded study evaluating the efficacy and safety of peginterferon alfa-2a (40KD) (PEGASYS (R)) alone or in combination with lamivudine vs lamivudine in 546 patients with HBeAg-negative/anti-HBe-positive chronic hepatitis B.." 54th Annual Meeting of the American-Association-for-the-Study-of-Liver-Disease , BOSTON, MASSACHUSETTS, 2003

Marcellin, P. Et Al. (2003) . "A phase III, partially double-blinded study evaluating the efficacy and safety of peginterferon alfa-2a (40KD) (PEGASYS (R)) alone or in combination with lamivudine vs lamivudine in 546 patients with HBeAg-negative/anti-HBe-positive chronic hepatitis B.." 54th Annual Meeting of the American-Association-for-the-Study-of-Liver-Disease , BOSTON, MASSACHUSETTS.

@conferencepaper{conferencepaper, author={P Marcellin Et Al. }, title={A phase III, partially double-blinded study evaluating the efficacy and safety of peginterferon alfa-2a (40KD) (PEGASYS (R)) alone or in combination with lamivudine vs lamivudine in 546 patients with HBeAg-negative/anti-HBe-positive chronic hepatitis B.}, congress name={54th Annual Meeting of the American-Association-for-the-Study-of-Liver-Disease}, city={BOSTON}, country={MASSACHUSETTS}, year={2003}}